• 10 minuti fa

Categoria

🗞
Novità
Trascrizione
00:00Professor, why are the new data from the Ideal study on the efficacy of Sela Delfar in patients with ALP so important?
00:11baseline 1 to 1.67 for ULN?
00:18This is a category of patients that until now had never been included in randomized controlled trials.
00:26We know well that until now traditionally the alkaline phosphatase target that was recommended was a target below
00:361.67 or under 1.5 depending on the endpoints that were chosen.
00:46However, the new guidelines, based on evidence, recommend, especially in the highest risk patient categories,
00:54normal alkaline phosphatase.
00:56So the Ideal study what it wanted to do is randomize patients to an alkaline phosphatase between 1 and
01:081.67 and evaluate the effectiveness of Sela Delfar in that target population.
01:14The study was positive, the endpoint was reached, 75% of the patients treated compared to 16
01:23% of patients in the placebo arm normalized alkaline phosphatase.
01:29This is important because it shows us that Sela Delfar is capable of doing this.
01:34This means that in patients in whom, on the basis of the risk profile, the clinician decides that the target
01:41Ideal treatment is a normal alkaline phosphatase, we can use Sela Delfar to achieve that goal.
01:51The study data are very encouraging; as we said, a large percentage of the enrolled patients achieved normalization.
02:03We also keep in mind that in this study the endpoint was a composite endpoint, so not only the normalization
02:09of alkaline phosphatase, but also a reduction of at least 15% compared to the baseline value.
02:15This is important because having very low alkaline phosphatase values ​​actually allows us to be sure that this is
02:27a solid result, so it is not just the reduction of a few points of phosphatase that perhaps allows us to get back
02:35within normal limits, but a significant reduction, therefore at least 15%.
02:40In addition to speed, Sela Delfar also demonstrates a long-lasting response, so I ask her how important it is to have these
02:51evidence in long-term management of PBC?
02:56We know that primary biliary cholangitis is a disease with a long natural history, which means that most
03:04some patients will have to live with the disease for decades, probably a very long and significant number of years.
03:15Precisely for this reason it is important to be sure that the second line treatment, in this case Sela Delfar actually
03:23have a long-lasting effectiveness.
03:27The Ashur study, which is still ongoing, the results of which have been presented at 48 months, tells us
03:34see and it comforts us to see how effectively the duration of the treatment is associated with a response that lasts
03:44over time.
03:45More than 30% of patients who were enrolled in Ashur achieved normalization of alkaline phosphatase with
03:54a 45% reduction in phosphatase values ​​from baseline at 48 months.
04:03This is a significant number of patients and it reaches the treatment target.
04:08One of the most important elements is also that these results are achieved also in what we consider a profile
04:16high risk.
04:17So young patients under 62 years of age in the study, patients who have a higher liver stiffness value
04:27at 10 kg pascal,
04:28therefore they are patients who have a higher probability of having events related to the disease.
04:39The study also shows that these data are confirmed in patients who had previously been treated with both
04:47with beticholic acid and with fibrates.
04:49So actually a robust response profile over time, not only in patients with milder disease,
04:59but also in patients with more advanced disease and a higher risk profile.
05:04In addition to the results on biochemical indicators, it also emerged that if DELFA acts on mechanisms associated with inflammation and
05:14fibrosis,
05:14How do these data translate into concrete benefits for patients with PBC?
05:23So, we know that PIPARs are drugs that have a particularly varied action profile.
05:32and also that they bring important benefits to patients with primary biliary cholangitis.
05:38Not only are they able to improve cholestasis, but they also have an anti-inflammatory profile at the liver level.
05:50which certainly improves disease control.
05:56A study on a recent proteomic analysis was presented at the American congress
06:03which actually shows how patients treated with seladelpar have a significant reduction
06:11of markers of cholestasis, inflammation, reduction of fibrosis
06:17and also a reduction in some metabolites that have been associated with itching.
06:24So actually that clinical benefit that we see in patients
06:28It is also confirmed in a series of serum markers
06:32which actually allow us to understand a little more about the mechanisms of action of drugs.
06:39This is a study that was conducted in a cohort of 180 patients treated with seladelpar,
06:47therefore a significant number of patients,
06:49which actually comforts us in understanding how much the drug can have a beneficial effect
06:59which goes beyond a reduction in alkaline phosphatase alone.

Consigliato